Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3ENQ51
Thu, 12.12.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma with strong growth and record margin after solid year-end finish
All 2024 targets met including raised revenue guidance: 12% revenue growth and EBITDA margin of 27.8%, both at constant currencies
Q4 2024 revenues reached EUR 237m; EBITDA margin of 27.9% well above prior year
FY 2024 revenues reached EUR 957m; EBITDA margin of 26.9 [ … ]
Wed, 04.12.2024
SCHOTT Pharma AG & Co. KGaA
Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges
New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges [ … ]
Thu, 26.09.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”
Market advances adoption of ready-to-use containers
Improved operational efficiency in pharmaceutical manufacturing processes
Increased patient safety with high-quality sterile primary packaging
SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), a pioneer [ … ]
Thu, 05.09.2024
SCHOTT Pharma AG & Co. KGaA
Promotion for SCHOTT Pharma: Listed on the MDAX for the first time
SCHOTT Pharma to join the 90 most important shares listed on the Frankfurt stock exchange as of September 23, 2024
MDAX promotion proves confidence in the company’s business model, strategic focus and ideal market position
The shares of SCHOTT Pharma AG & Co. KGaA, a global [ … ]
Thu, 29.08.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance
Q3 2024 revenues up 21% yoy to EUR 268m at constant currencies
Strong Q3 2024 EBITDA margin of 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first nine month of FY 2024
SCHOTT Pharma increases revenue guidance [ … ]
Thu, 08.08.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
August 8, 2024, Germany, Mainz
SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C.
The independent Science Based Targets initiative (SBTi) has validated the clima [ … ]
Wed, 31.07.2024
SCHOTT Pharma AG & Co. KGaA
Transforming operational efficiency and sustainability: SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes
31 July 2024, Germany, Mainz
SCHOTT Pharma’s new nest holds 160 prefillable polymer syringes, which marks an increase of 60 syringes per nest.
The new nest design allows pharma companies to increase the [ … ]
Tue, 16.07.2024
SCHOTT Pharma AG & Co. KGaA
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
16 July 2024, Germany, Mainz
SCHOTT Pharma introduces new 10ml ready-to-use (RTU) cartridges, specifically designed to store highly sensitive biologics used to treat cancer, metabolic disorders, cardiovascular [ … ]
Thu, 27.06.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies
Q2 2024 EBITDA margin of 27.0% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024
Guidance for fiscal year 2024 confirmed
SCHOTT Pharma, a pioneer [ … ]
Thu, 27.06.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies
Q2 2024 EBITDA margin of 27.0% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024
Guidance for fiscal year 2024 confirmed
SCHOTT Pharma, a pioneer [ … ]